Get the Stockscreener App
3.41
2.29%
-0.08
After Hours:
3.41
Agenus Inc stock is traded at $3.41, with a volume of 547.36K.
It is down -2.29% in the last 24 hours and up +5.57% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$3.49
Open:
$3.5
24h Volume:
547.36K
Relative Volume:
0.61
Market Cap:
$142.00M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
2.0425
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
+8.25%
1M Performance:
+5.57%
6M Performance:
-1.73%
1Y Performance:
-43.82%
1-Day Range:
$3.41
$3.55
1-Week Range:
$3.02
$3.55
52-Week Range:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.41 | 127.43M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Form 4 Agenus Inc For: 30 June By Investing.com - Investing.com Australia
Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares - Stock Titan
Agenus Inc.(NasdaqCM: AGEN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2500 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Growth Benchmark - marketscreener.com
Durable Outcomes in MSS Metastatic Colorectal Cancer Without Active Liver MetastasesAgenus - Oncodaily
Price to sales forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to revenue forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Price to book forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Agenus Inc. Actuals & Estimates (BX:AGEN) - TradingView
Agenus Inc. Actuals & Estimates (NASDAQ:AGEN) - TradingView
AGEN Forecast — Price Target — Prediction for 2027 - TradingView
Agenus Inc. Actuals & Estimates (TRADEGATE:AJ8) - TradingView
Agenus to present 3-year cancer trial data at ESMO conference - Investing.com South Africa
Agenus Challenges 'Untreatable' Status of a Common Colorectal Cancer - BriefGlance
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - BioSpace
Agenus (AGEN) Set to Present Promising Survival Data at ESMO 202 - GuruFocus
Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026 - TradingView
Agenus Inc (AGEN) Institutional Confidence - TradingKey
Speed and Rigor Are Not in Conflict – Garo Armen - Oncodaily
Form 8K Agenus Inc For: 23 June By Investing.com - Investing.com Nigeria
Agenus Inc. Files Form 8-K with SEC: Corporate Details, Stock Information & Key Disclosures (June 16, 2026) 25 - Minichart
Agenus Shareholders Approve Governance, Compensation and Auditors - TipRanks
Form 8K Agenus Inc For: 23 June - Investing.com UK
Agenus (NASDAQ: AGEN) investors approve equity plan changes and KPMG - Stock Titan
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agenus Inc (AGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agenus Inc (AGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AGEN Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Agenus Inc (AGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Agenus Inc (AGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Are options traders betting on a big move in Agenus stock? - MSN
Agenus annual meeting: BOT/BAL leads cancer drug push as balance sheet improves - MSN
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves - TradingView
Agenus (NASDAQ: AGEN) pays Dr. Garo Armen salary in stock grant - Stock Titan
Why is Agenus (AGEN) down 9.6% since last earnings report? - MSN
Agenus Inc. (AGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report? - Yahoo Finance
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):